{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:01:32Z","timestamp":1782903692234,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"am","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.therap.2022.07.009","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T10:58:36Z","timestamp":1659351516000},"page":"279-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Vaccines and Bell's palsy: A narrative review"],"prefix":"10.1016","volume":"78","author":[{"given":"Blandine","family":"Bertin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Grenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Pizzoglio-Billaudaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Lepelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Atzenhoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-581X","authenticated-orcid":false,"given":"Thierry","family":"Vial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2022.07.009_bib0240","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12887-021-02571-w","article-title":"The facial nerve palsy and cortisone evaluation (FACE) study in children: protocol for a randomized, placebo-controlled, multicenter trial, in a Borrelia burgdorferi endemic area","volume":"21","author":"Karlsson","year":"2021","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.therap.2022.07.009_bib0245","first-page":"1454","article-title":"Rabies vaccine accidents; pseudo peritoneal syndrome and successive bilateral facial paralysis","volume":"18","author":"Zabludovich","year":"1946","journal-title":"Dia Med"},{"key":"10.1016\/j.therap.2022.07.009_bib0250","series-title":"Priority list of Adverse Events of Special Interest: COVID 19","year":"2020"},{"key":"10.1016\/j.therap.2022.07.009_bib0255","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.therap.2021.05.003","article-title":"French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge","volume":"76","author":"Lacroix","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.07.009_bib0260","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1111\/ene.15371","article-title":"Surge of Bell's Palsy in the era of\u00a0COVID-19: systematic review","volume":"29","author":"Gupta","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.therap.2022.07.009_bib0265","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/oxfordjournals.aje.a114808","article-title":"Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years","volume":"127","author":"Shaw","year":"1988","journal-title":"Am J Epidemiology"},{"key":"10.1016\/j.therap.2022.07.009_bib0270","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pds.3593","article-title":"Post-licensure safety surveillance for human papillomavirus-16\/18-AS04-adjuvanted vaccine: more than 4 years of experience","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiology Drug Saf"},{"key":"10.1016\/j.therap.2022.07.009_bib0275","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/imj.13005","article-title":"Adverse event monitoring of the human papillomavirus vaccines in Scotland","volume":"46","author":"Cameron","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.therap.2022.07.009_bib0280","doi-asserted-by":"crossref","first-page":"E648","DOI":"10.1503\/cmaj.170871","article-title":"Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study","volume":"190","author":"Liu","year":"2018","journal-title":"CMAJ"},{"issue":"49 PtB","key":"10.1016\/j.therap.2022.07.009_bib0285","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1016\/j.vaccine.2017.09.032","article-title":"Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine","volume":"35","author":"Hansen","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.therap.2022.07.009_bib0290","doi-asserted-by":"crossref","first-page":"e20162084","DOI":"10.1542\/peds.2016-2084","article-title":"Safety of quadrivalent meningococcal conjugate vaccine in 11- to 21-year-olds","volume":"139","author":"Tseng","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.therap.2022.07.009_bib0295","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2796.2011.02474.x","article-title":"Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study","volume":"271","author":"Tseng","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.therap.2022.07.009_bib0300","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Tavares-Da-Silva","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.therap.2022.07.009_bib0305","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4161\/hv.2790","article-title":"Bell's palsy and parenteral inactivated influenza vaccine","volume":"2","author":"Stowe","year":"2006","journal-title":"Human Vaccines"},{"key":"10.1016\/j.therap.2022.07.009_bib0310","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy100","article-title":"Pneumococcal conjugate vaccine safety in elderly adults","volume":"5","author":"Tseng","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.therap.2022.07.009_bib0315","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/aje\/kws011","article-title":"Immunization and Bell's palsy in children: a case-centered analysis","volume":"175","author":"Rowhani-Rahbar","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.therap.2022.07.009_bib0320","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.4161\/21645515.2014.972149","article-title":"Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials","volume":"10","author":"Vaughn","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.therap.2022.07.009_bib0325","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/vaccines9070746","article-title":"Association between influenza vaccination and the risk of Bell's palsy in the Korean elderly","volume":"9","author":"Jeong","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.therap.2022.07.009_bib0330","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amepre.2011.04.004","article-title":"H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink Project","volume":"41","author":"Lee","year":"2011","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.therap.2022.07.009_bib0335","doi-asserted-by":"crossref","first-page":"e0175539","DOI":"10.1371\/journal.pone.0175539","article-title":"Bell's palsy and influenza(H1N1)pdm09 containing vaccines: a self-controlled case series","volume":"12","author":"Wijnans","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2022.07.009_bib0340","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/pds.4347","article-title":"Observational safety study of specific outcomes after trivalent cell culture seasonal influenza vaccination (Optaflu\u00ae) among adults in THIN database of electronic UK primary healthcare records","volume":"27","author":"Hall","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2022.07.009_bib0345","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.vaccine.2017.01.062","article-title":"Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49 years","volume":"35","author":"Baxter","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.therap.2022.07.009_bib0350","doi-asserted-by":"crossref","first-page":"d5956","DOI":"10.1136\/bmj.d5956","article-title":"Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden","volume":"343","author":"Bardage","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2022.07.009_bib0355","first-page":"505","article-title":"VAERS Working Group. Pharmacoepidemiol. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001","volume":"13","author":"Zhou","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2022.07.009_bib0360","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40261-020-00952-0","article-title":"Facial paralysis following influenza vaccination: a disproportionality analysis using the Vaccine Adverse Event Reporting System Database","volume":"40","author":"Kamath","year":"2020","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.therap.2022.07.009_bib0365","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.vaccine.2012.01.013","article-title":"The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis","volume":"30","author":"Huang","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.therap.2022.07.009_bib0370","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2022.07.009_bib0375","doi-asserted-by":"crossref","first-page":"e6999","DOI":"10.1371\/journal.pone.0006999","article-title":"Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin","volume":"4","author":"Lewis","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.therap.2022.07.009_bib0380","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.294.21.2720","article-title":"Adverse events reported following live, cold-adapted, intranasal influenza vaccine","volume":"294","author":"Izurieta","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2022.07.009_bib0385","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1016\/j.vaccine.2019.07.025","article-title":"Case report: recurrent peripheral facial paralysis following two influenza vaccinations in 2009 and 2016","volume":"37","author":"Gocko","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.therap.2022.07.009_bib0390","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.therap.2021.03.005","article-title":"Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy","volume":"76","author":"Soeiro","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.07.009_bib0395","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1473-3099(21)00076-1","article-title":"Bell's palsy and SARS-CoV-2 vaccines","volume":"21","author":"Ozonoff","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.therap.2022.07.009_bib0400","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1473-3099(21)00273-5","article-title":"Bell's palsy and SARS-CoV-2 vaccines - an unfolding story","volume":"21","author":"Cirillo","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.therap.2022.07.009_bib0405","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijid.2021.08.071","article-title":"Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database","volume":"111","author":"Sato","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.therap.2022.07.009_bib0410","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamainternmed.2021.2219","article-title":"Association of facial paralysis with mRNA COVID-19 vaccines: a disproportionality analysis using the World Health Organization pharmacovigilance database","volume":"181","author":"Renoud","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.therap.2022.07.009_bib0415","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2022.07.009_bib0420","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for adverse events after COVID-19 mRNA vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2022.07.009_bib0425","article-title":"Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines","volume":"2","author":"McMurry","year":"2021","journal-title":"Med (N Y)"},{"key":"10.1016\/j.therap.2022.07.009_bib0430","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmi.2021.09.018","article-title":"Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study","volume":"28","author":"Shasha","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.therap.2022.07.009_bib0435","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"J Nat Med"},{"key":"10.1016\/j.therap.2022.07.009_bib0440","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoto.2021.1259","article-title":"Association of COVID-19 vaccination and facial nerve palsy: a case-control study","volume":"147","author":"Shemer","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.therap.2022.07.009_bib0445","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1473-3099(21)00451-5","article-title":"Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study","volume":"22","author":"Wan","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.therap.2022.07.009_bib0450","doi-asserted-by":"crossref","first-page":"100236","DOI":"10.1016\/j.lanepe.2021.100236","article-title":"Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study","volume":"11","author":"Shibli","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.therap.2022.07.009_bib0455","doi-asserted-by":"crossref","first-page":"e243829","DOI":"10.1136\/bcr-2021-243829","article-title":"Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses","volume":"14","author":"Burrows","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.therap.2022.07.009_bib0460","doi-asserted-by":"crossref","first-page":"244","DOI":"10.11604\/pamj.2021.40.244.31498","article-title":"Paralysie faciale p\u00e9riph\u00e9rique post-vaccination COVID-19\u00a0: \u00e0 propos d\u2019un cas","volume":"40","author":"Kharoubi","year":"2021","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.therap.2022.07.009_bib0465","doi-asserted-by":"crossref","first-page":"101259","DOI":"10.1016\/j.ajoc.2022.101259","article-title":"Bell's palsy following COVID-19 vaccine administration in HIV+ patient","volume":"25","author":"Mussatto","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.therap.2022.07.009_bib0470","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/brainsci12030407","article-title":"COVID-19 vaccination and neurological manifestations: a review of case reports and case series","volume":"12","author":"Sriwastava","year":"2022","journal-title":"Brain Sci"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722001378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722001378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:28Z","timestamp":1758567328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595722001378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0040595722001378"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.07.009","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccines and Bell's palsy: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}